This is an article from the Dec. 11, 2017 issue of THE DARK REPORT. The complete article is available for a limited time to all readers. This article plus a full analysis of 2017 developments in the PAMA process are available at all times to paid members of the Dark Intelligence Group.
IT’S A LONG-AWAITED DEVELOPMENT!
Genetic testing for dogs is the goal of Embark Veterinary, of Boston, Mass. Founded in 2015, the company just raised $4.5 million from investors, including Anne Wojcicki, founder of 23andMe. Company executives say the genetic testing will help vets, pet owners, and breeders identify the disease risk of the dogs, as well as the animals’
CEO SUMMARY: To fill the unmet demand for quality clinical laboratory testing in China, a partnership between pathologists at UCLA and Centre Testing International Corp. of Shenzen have built and will operate a lab facility in Shanghai. The new lab will open by late September and will initially provide core lab testing services to pharmaceutical
HOW LONG CAN IT TAKE FOR A HEALTHCARE SYSTEM to underfund clinical lab testing and anatomic pathology services before this ongoing financial erosion becomes visible in the form of systemic quality problems with lab tests?
I believe the United States is now on the path to learning the answer to this question. As you will read
CEO SUMMARY: Interest by office-based physicians in creating an in-clinic medical testing laboratory is on the increase. This has direct consequences for independent commercial labs, hospital lab outreach programs, and anatomic pathology groups, since office- based physicians are a primary source of lab test referrals. One consultant says that 60% to 70% of the volume
CEO SUMMARY: Two strong trends in laboratory management can be seen in the College of American Pathologists’ (CAP) move to offer accreditation to ISO 15189:2007. The first trend is the movement toward quality management systems such as Lean and Six Sigma. The second trend is the global convergence of laboratory operations. Also, a growing number
CEO SUMMARY: PerkinElmer’s interest in the multiplex capabilities of Luminex’s xMap technology led to this new licensing agreement. PerkinElmer’s instrument systems played a major role in accelerating the work of the Human Genome Project. Now, besides bioresearch applications, PerkinElmer wants to look for opportunities to develop high-volume, multi-analyte assays for in vitro diagnostics.
CEO SUMMARY: Here’s a little-known side to diagnostics giant Beckman Coulter Inc. Its efforts to expand into the fields of biomedical R&D and clinical research is a strategic shift designed to give it early access to promising technology that could be introduced into the clinical diagnostics marketplace. In this exclusive interview, John (Jack) Wareham, Chair,
This chapter addresses the characteristics of the laboratory industry which define the starting point for changes and ongoing evolution. The eight business premises listed in this White Paper describe unique situations which directly influence the ability of clinical laboratories to serve the medical community.
The relevance of these business premises becomes apparent whenever a laboratory undertakes